Stefania Bellone, PhD
Stefania Bellone, PhD
Assoc Rsrch Scientist Ob/Gyn
Yale University School of Medicine
333 Cedar Street
New Haven,
CT
USA
06520
Papers:
140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
401
Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma